BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Venous Thromboembolism readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Venous Thromboembolis
 m\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07015905-11309@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07015905)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee A
 rthroplasty in Adults\nEstimated primary completion: 20 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07015905
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213778-11309@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07213778)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After To
 tal Knee Arthroplasty in Adult Participants\nEstimated primary completion:
  17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07213778
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697599-11309@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290625
DTEND;VALUE=DATE:20290626
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07697599)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: Venous 
 Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and 
 Adolescent Participants With a Peripherally Inserted Central Catheter (PIC
 C)\nEstimated primary completion: 25 June 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07697599
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493304-11309@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20310718
DTEND;VALUE=DATE:20310719
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07493304)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: Treatme
 nt and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Parti
 cipants With Solid and Hematologic Cancers\nEstimated primary completion: 
 18 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07493304
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
